Pharmaceuticals
Cryptococcosis After Initiation of Janus Kinase Inhibitors or Biologic DMARDs in Rheumatoid Arthritis: Three Pairwise Active-Comparator Analyses of Propensity Score-Matched TriNetX Cohorts, 2005–2025
Door Ying Xiu Tay, Yiting He, Malcolm Koo en 1 anderen.
Inhoud in het Engels
Abstract
Background/Objectives: Comparative safety evidence for cryptococcosis during advanced rheumatoid arthritis (RA) therapy is limited. We compared newly recorded cryptococcosis after initiation of Janus kinase inhibitors (JAKi), tumor necrosis factor (TNF) inhibitors (TNFi), and non-TNF biologic disease-modifying antirheumatic drugs (non-TNF bDMARDs).